Satoshi Morita

Research interests

Publications

• Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30035-x

• Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.01488

• 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

  Renal Replacement Therapy · 2017 · https://doi.org/10.1186/s41100-017-0114-y

• 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

  Renal Replacement Therapy · 2017 · https://doi.org/10.1186/s41100-017-0114-y

• Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model

  Nature · 2017 · https://doi.org/10.1038/nature23664

• Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw206

• Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

  The Lancet Haematology · 2015 · https://doi.org/10.1016/s2352-3026(15)00196-9

• Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.62.3397

• Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.48.5805

• Peripheral Endothelial Function and Cardiovascular Events in High‐Risk Patients

  Journal of the American Heart Association · 2013 · https://doi.org/10.1161/jaha.113.000426

• Sentinel Node Mapping for Gastric Cancer: A Prospective Multicenter Trial in Japan

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2013.50.3789

• Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

  The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70490-x

• Association Between Gait Speed as a Measure of Frailty and Risk of Cardiovascular Events After Myocardial Infarction

  Journal of the American College of Cardiology · 2013 · https://doi.org/10.1016/j.jacc.2013.02.020

• Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease

  Neurology · 2012 · https://doi.org/10.1212/wnl.0b013e318249f71f

• Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds214

• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa0909530

• Simple and Accurate Electrocardiographic Criteria to Differentiate Takotsubo Cardiomyopathy From Anterior Acute Myocardial Infarction

  Journal of the American College of Cardiology · 2010 · https://doi.org/10.1016/j.jacc.2009.12.059

• Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma

  Cancer · 2010 · https://doi.org/10.1002/cncr.25314

• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

  The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70364-x

• First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.18.7658

• Synthesis and structure of smectic clay/poly(methyl methacrylate) and clay/polystyrene nanocomposites via in situ intercalative polymerization

  Polymer · 2000 · https://doi.org/10.1016/s0032-3861(99)00655-2

Current projects

No projects listed.